copper tripeptide-1 comes up often in conversation and rarely with the context attached. Here we lay out the basics in order, then work through the practical considerations.
Last reviewed on 2025-12-17. Where a claim depends on a specific study, the study is described rather than over-claimed.
Solid GHK-Cu appears as a blue to blue-violet powder, and the colour is a direct consequence of copper coordination. The complex dissolves readily in water and in many polar solvents, while the free peptide behaves differently. Solubility in nonpolar media is low, which limits its use in oil-based systems. Solutions are typically prepared fresh because the dissolved form is more exposed to hydrolysis and to loss of the metal ion than the dry powder. Working concentrations are usually low, and preparation notes often specify the solvent and the order of addition.
Dry material is typically held at low temperature, often around minus twenty degrees Celsius, and protected from moisture and light. Copper complexes can release their metal ion under acidic conditions or in the presence of competing chelators. Hydrolysis of the peptide backbone is a slower but real pathway, and the histidine residue is susceptible to oxidation over long periods. Stability statements therefore depend on formulation, pH, and container, and they should be read as conditional rather than absolute.
GHK-Cu is the copper-binding complex formed by the tripeptide glycyl-L-histidyl-L-lysine and a copper(II) ion. The free peptide is usually written as GHK, and the complex is written as GHK-Cu or Cu-GHK. The sequence was identified in human plasma and later detected in saliva and urine. Its name comes from the single-letter codes of glycine, histidine and lysine. The complex is widely described as a naturally occurring carrier of copper in blood rather than as a free peptide with its own hormonal role.
Copper binds to the peptide through the histidine imidazole nitrogen and the terminal amino group, forming a stable square-planar complex. Binding constants reported for copper(II) with GHK are high, so the peptide competes effectively for copper in solution. The complex absorbs visible light, which gives solutions a blue to violet colour. Whether the metal-free peptide has a distinct biological function of its own is still an open question; some work treats it mainly as a copper delivery vehicle, while other work reports peptide-specific effects.
The compound was first isolated from human plasma in the 1970s by Loren Pickart, who later described copper-binding activity in liver and other tissues. Early reports focused on its presence in blood and its ability to carry copper between proteins. Commercial and cosmetic use of the term 'copper peptide' has since broadened, and labels rarely distinguish GHK-Cu from other copper-binding fragments. This naming overlap makes literature searching harder, because cosmetic ingredient lists, supplier catalogues and laboratory papers use different vocabularies for the same molecule.
| Property | Value | Notes |
|---|---|---|
| Solubility | Soluble in water | Free peptide differs from the complex |
| Typical storage | approx. −20 °C, desiccated | Protect from light and moisture |
| Primary purity method | RP-HPLC with MS | Confirms peptide identity |
| Copper assay | ICP-MS or AAS | Measured separately from peptide purity |
| Main degradation routes | Metal loss, hydrolysis, oxidation | Rate depends on pH and matrix |
GHK-Cu is a coordination complex formed between the peptide glycyl-L-histidyl-L-lysine and a copper(II) ion. The unbound chain, abbreviated GHK, consists of three amino acids and occurs naturally in human plasma, saliva, and urine. Binding of the metal is mediated mainly by the imidazole nitrogen of the histidine residue together with backbone amides, producing a stable chelate. Ingredient nomenclature often lists the same substance as copper tripeptide-1. Its charge and solubility behaviour differ from those of the metal-free chain.
The copper-binding activity of this sequence was described in the 1970s during studies of liver tissue and plasma factors. Early work identified the peptide as a component that influenced copper uptake by cells and that appeared in wound fluid. Later investigations examined its presence across species, reporting the same chain in human and animal samples. A decline in measured concentration with age became a recurring observation, although the underlying causes remain incompletely characterised.
Laboratory characterization of GHK-Cu typically combines separation, spectroscopic, and elemental techniques. Reverse-phase high-performance liquid chromatography is widely used to assess peptide purity, often with ultraviolet detection near the copper-related absorption band or with mass spectrometry for identity confirmation. Because the molecule contains copper, elemental methods such as inductively coupled plasma mass spectrometry or atomic absorption spectroscopy are used to quantify metal content and confirm stoichiometry. No single universal pharmacopeial monograph exists for GHK-Cu. Laboratories therefore validate their own methods, and reported purity values depend on the chosen assay and calibration standards.
Stability of GHK-Cu is influenced by light, oxygen, moisture, pH, and temperature. Solid material is generally kept desiccated and frozen to reduce hydrolysis and oxidation, while aqueous solutions are best prepared fresh or stored cold in aliquots. Repeated freeze-thaw cycles can promote aggregation, precipitation, or peptide degradation. Copper coordination may change under strongly acidic or alkaline conditions, potentially altering the complex's spectroscopic properties. Published long-term stability data for specific matrices, such as cosmetic emulsions or biological buffers, are limited, so shelf-life claims should be treated as formulation-specific rather than universal.
GHK-Cu is a coordination complex formed between the tripeptide glycyl-L-histidyl-L-lysine and a copper(II) ion. The peptide backbone consists of glycine, histidine, and lysine joined in that order. Copper is held through the imidazole nitrogen of histidine and the alpha-amino group at the N-terminus, which together produce a square-planar arrangement around the metal center. The solid appears blue to violet, a color that originates from d-d electronic transitions within the copper coordination sphere. The complex is indexed under CAS number 89030-95-5.
The sequence now called GHK was first reported in the early 1970s after isolation from human plasma, where it was noted to influence liver cell behavior in laboratory preparations. Later work described a copper-binding form and its activity in fibroblast and wound-model experiments. Review articles frequently group the substance with other copper peptides. Concentrations in blood appear to fall with age in several small surveys, although the reason for this trend is not settled. Whether such a decline carries functional consequences remains an open question.
Copper(II) binds the peptide through four nitrogen donors: the terminal amino group, the imidazole nitrogen of histidine, and two deprotonated amide nitrogens of the peptide backbone. This tetradentate arrangement gives a roughly square-planar geometry, the thermodynamically favoured form near neutral pH. Because the amide nitrogens must lose a proton before they can coordinate, complex formation is strongly pH-dependent, and the fully coordinated species dominates only above mildly acidic conditions. Electronic transitions within the copper d orbital set produce the characteristic blue to violet colour in aqueous solution.
Endogenous GHK occurs in blood plasma, saliva, and urine, and reported plasma concentrations decline with age in several studies. Researchers have proposed that the peptide acts as a copper carrier that delivers the metal to cells and to sites of injury. That transport role is a hypothesis supported by binding measurements and tissue-distribution data rather than a settled mechanism, and the peptide is generally described as a minor contributor to total plasma copper transport. Values reported in wound fluid and certain tissue extracts are higher than in circulating plasma.
Recent research involving MOFs as a drug delivery method includes more than just the encapsulation of everyday drugs like ibuprofen and aspirin. In early 2018 Chen et al., published detailing their work on the use of MOF, ZIF-8 (zeolitic imidazolate framework-8) in antitumor research "to control the release of an autophagy inhibitor, 3-methyladenine (3-MA), and prevent it from dissipating in a large quantity before reaching the target." The group performed in vitro studies and determined that "the autophagy-related proteins and autophagy flux in HeLa cells treated with 3-MA@ZIF-8 NPs show that the autophagosome formation is significantly blocked, which reveals that the pH-sensitive dissociation increases the efficiency of autophagy inhibition at the equivalent concentration of 3-MA." This shows promise for future research and applicability with MOFs as drug delivery methods in the fight against cancer.
=== Supreme Council of Colon === Cassard departed from New York City and arrived in the port of Santiago de Cuba in December 1859, personally despatched by Albert Pike. When he arrived in the city, he never left the ship. Since there was an active warrant for his arrest in Cuba, he was afraid that if he did disembark, he might have been taken into custody and executed. On December 27, 1859, in the cabin of his ship, Andrés Cassard established a Supreme Council of the Ancient and Accepted Scottish Rite, 33°, at the direction of the Supreme Council, 33°, Southern Jurisdiction. The first Grand Commander of the Supreme Council was Antonio Vinent y de Gola, V Marqués de Palomares del Duero, one of the wealthiest property owners in Oriente Province. He had earned the title of Marquis in the service of the government against the independence movement. In 1860, a rift started to form between the Grand Lodge of Colon and the Supreme Council of Colon. This rift between the Supreme Council and the Grand Lodge was about more than the ability to charter Lodges, it was deeply rooted in the different political ideologies between Protestants and Catholics. While Freemasons in the capitol in Havana maintained closer links to the United States, the Eastern city of Santiago de Cuba was much closer culturally to the Catholicism in the rest of Latin America. Being predominately Catholic landowners, the Supreme Council viewed the Grand Lodge as one filled with Protestantism and Anglo-Saxon ideas.
The company partnered with Baptist Memorial Health Care to establish a bacteriology centre of excellence (Memphis, Tennessee), with Western Connecticut Health Network to form Constitution Diagnostics Network, and with NYU Health System to form NYU Langone Diagnostics (New York). In 2018, Sonic acquired Pathology Trier (Germany). The company partnered with ProMedica Health System to form ProMedica Pathology Laboratories (Ohio and adjacent states). In 2019, the company acquired Aurora Diagnostics (USA) and sold its interest in GLP systems (Germany). In 2020–2021, Sonic acquired Pathologie Hamburg, a majority stake in Epworth Medical Imaging (Victoria, Australia) and in Harrison.ai's pathology solutions, Canberra Imaging Group, and ProPath (Dallas, Texas). In 2022, Sonic acquired a 19.99% state in Microba Life Sciences Limited - ASX:MAP (Queensland, Australia). Sonic and Microba have agree on a strategic alliance to exclusively deliver Microba's microbiome testing Technology in Germany, the United Kingdom and Belgium as well as a non-exclusive distribution within Sonic's broader network including Australia, Switzerland, the United States and New Zealand.
Sources: en.wikipedia.org
Glutamate-cysteine ligase regulatory subunit is an enzyme that in humans is encoded by the GCLM gene. Glutamate-cysteine ligase, also known as gamma-glutamylcysteine synthetase, is the first rate limiting enzyme of glutathione synthesis. The enzyme consists of two subunits, a heavy catalytic subunit and a light regulatory subunit. Gamma glutamylcysteine synthetase deficiency has been implicated in some forms of hemolytic anemia.
Trastuzumab, sold under the brand name Herceptin among others, is a monoclonal antibody used to treat breast cancer and stomach cancer. It is specifically used for cancer that is HER2 receptor positive. It may be used by itself or together with other chemotherapy medication. Trastuzumab is given by slow injection into a vein and injection just under the skin. Common side effects include fever, infection, cough, headache, trouble sleeping, and rash. Other severe side effects include heart failure, allergic reactions, and lung disease. Use during pregnancy may harm the baby. Trastuzumab works by binding to the HER2 receptor and slowing down cell replication. Trastuzumab was approved for medical use in the United States in September 1998, and in the European Union in August 2000. It is on the World Health Organization's List of Essential Medicines.
Pharmacology: the study of the biochemical and physiological effects of drugs on human beings. Pharmacodynamics: the study of the cellular and molecular interactions of drugs with their receptors. Simply "What the drug does to the body" Pharmacokinetics: the study of the factors that control the concentration of drug at various sites in the body. Simply "What the body does to the drug" Pharmaceutical toxicology: the study of the harmful or toxic effects of drugs. Pharmacogenomics: the study of the inheritance of characteristic patterns of interaction between drugs and organisms. Pharmaceutical chemistry: the study of drug design to optimize pharmacokinetics and pharmacodynamics, and synthesis of new drug molecules (Medicinal Chemistry). Pharmaceutics: the study and design of drug formulation for optimum delivery, stability, pharmacokinetics, and patient acceptance. Pharmacognosy: the study of medicines derived from natural sources. As new discoveries advance and extend the pharmaceutical sciences, subspecialties continue to be added to this list. Importantly, as knowledge advances, boundaries between these specialty areas of pharmaceutical sciences are beginning to blur. Many fundamental concepts are common to all pharmaceutical sciences. These shared fundamental concepts further the understanding of their applicability to all aspects of pharmaceutical research and drug therapy.
Sources: en.wikipedia.org
Many drug interactions are due to alterations in drug metabolism. Further, human drug-metabolizing enzymes are typically activated through the engagement of nuclear receptors. One notable system involved in metabolic drug interactions is the enzyme system comprising the cytochrome P450 oxidases.
Hemoglobin (haemoglobin, Hb or Hgb) is a protein containing iron that facilitates the transportation of oxygen in red blood cells. Almost all vertebrates contain hemoglobin, with the sole exception of the fish family Channichthyidae. Hemoglobin in the blood carries oxygen from the respiratory organs (lungs or gills) to the other tissues of the body, where it releases the oxygen to enable aerobic respiration which powers an animal's metabolism. A healthy human has 12 to 20 grams of hemoglobin in every 100 mL of blood. Hemoglobin is a metalloprotein, a chromoprotein, and a globulin. In mammals, hemoglobin makes up about 96% of a red blood cell's dry weight (excluding water), and around 35% of the total weight (including water). Hemoglobin has an oxygen-binding capacity of 1.34 mL of O2 per gram, which increases the total blood oxygen capacity seventy-fold compared to dissolved oxygen in blood plasma alone. The mammalian hemoglobin molecule can bind and transport up to four oxygen molecules. Hemoglobin also transports other gases. It carries off some of the body's respiratory carbon dioxide (about 20–25% of the total) as carbaminohemoglobin, in which CO2 binds to the heme protein. The molecule also carries the important regulatory molecule nitric oxide bound to a thiol group in the globin protein, releasing it at the same time as oxygen.
Intramembranous ossification is one of two key processes during fetal skeletal development and is an essential process during the natural healing of bone fractures. It forms the flat bones of the skull, mandible, and hip bone among others. Woven bone is formed when mesenchymal stem cells (MSCs), an unspecified cell that can develop into an osteoblast, initiate intramembranous ossification. First, a small group of adjacent MSCs differentiate into osteoblast and begin to replicate and form a small, dense cell clusters. This forms an ossification centre, at which point the osteoblasts begin secreting osteoid, an unmineralized collagen-proteoglycan matrix that can bind calcium. Binding calcium to the osteoid hardens the matrix and entraps the osteoblasts. This entrapment transforms the osteoblasts into osteocytes. As osteoblasts continue to secrete osteoid, it surrounds blood vessels and forms trabecular, cancellous, or spongy bone. Over time, these blood vessels develop into red bone marrow. MSCs on the bone's surface form the periosteum, a membrane covering the outer surface of bones. MSCs on the inner surface of the periosteum develop into osteoblasts and secrete osteoid parallel with the existing matrix, which creates layers. The result of this is compact or cortical bone.
Sources: en.wikipedia.org
The colour comes from electronic transitions in the coordinated copper(II) ion. Ligand field effects absorb part of the visible spectrum. A colourless or greenish sample may indicate degraded material.
Copper can be displaced by other metal ions, by strong chelating agents, or by low pH. Samples exposed to these conditions may contain a mixture of free peptide and complex. Analytical testing is the only reliable way to confirm the bound fraction.
Solution storage generally shortens shelf life compared with the dry powder. Hydrolysis and oxidation proceed faster in aqueous media. Where solutions are used, cold storage and short holding times reduce measurable change.
The letters GHK are the one-letter codes for glycine, histidine and lysine, the three amino acids in the peptide. The suffix Cu indicates that the peptide is bound to a copper ion, normally copper(II).